Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Presented at the American Heart Associations 2023 Scientific Sessions (1113 November, Philadelphia, USA), the results of the SELECT trial showed that overweight or obese people without diabetes taking semaglutide for more than three years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight
The patients were randomized 2:1:1 to receive subcutaneous injection of WEGOVY 2.4 mg, WEGOVY 1.7 mg, or placebo
Multiple injections may be needed over time
If your vial has been out for longer than allowed, discard it and use a fresh one
Most clients tolerate Tirzepatide well
US$ 25.63
US$ 29.69
US$ 29.76
US$ 23.42
